Monoclonal antibody-induced cytokine-release syndrome
…, G Treacy, E Bouman-Thio - Expert review of …, 2009 - Taylor & Francis
Monoclonal antibodies (mAbs) are widely used in anti-inflammatory and tumor therapy.
Although effective, mAbs can cause a variety of adverse effects. An important toxicity seen with a …
Although effective, mAbs can cause a variety of adverse effects. An important toxicity seen with a …
Pharmacokinetics and safety of golimumab, a fully human anti‐TNF‐α monoclonal antibody, in subjects with rheumatoid arthritis
…, RM Fleischmann, E Bouman‐Thio… - The Journal of …, 2007 - Wiley Online Library
Golimumab is a fully human antitumor necrosis factor alpha (TNF‐α) monoclonal antibody
that is being developed for intravenous and subcutaneous administration. To assess the …
that is being developed for intravenous and subcutaneous administration. To assess the …
Pharmacokinetics, pharmacodynamics and safety of a human anti‐IL‐6 monoclonal antibody (sirukumab) in healthy subjects in a first‐in‐human study
Z Xu, E Bouman‐Thio, C Comisar… - British journal of …, 2011 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Interleukin (IL)‐6 is a cytokine
known for pleiotropic and pro‐inflammatory functions. IL‐6 is involved in various disease …
known for pleiotropic and pro‐inflammatory functions. IL‐6 is involved in various disease …
Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects
…, B Frederick, H Yan, E Bouman‐Thio… - The Journal of …, 2010 - Wiley Online Library
This study characterized the pharmacokinetics (PK) of golimumab, an antitumor necrosis factor
alpha human IgG1k monoclonal antibody, after a single intravenous (IV) or subcutaneous …
alpha human IgG1k monoclonal antibody, after a single intravenous (IV) or subcutaneous …
First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis
…, C Calderon, SJ Marciniak, E Bouman-Thio… - European journal of …, 2016 - Springer
Purpose The purpose of this study is to evaluate the pharmacokinetics, immunogenicity,
safety, and tolerability of guselkumab, a human monoclonal antibody with high affinity and …
safety, and tolerability of guselkumab, a human monoclonal antibody with high affinity and …
A phase I, single and fractionated, ascending‐dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin …
E Bouman‐Thio, K Franson, B Miller… - The Journal of …, 2008 - Wiley Online Library
… (CNTO 528) in Healthy Male Subjects - Bouman‐Thio - 2008 - The Journal of Clinical
Pharmacology - Wiley Online Library … Dr Esther Bouman-Thio MD … Dr Esther Bouman-Thio MD …
Pharmacology - Wiley Online Library … Dr Esther Bouman-Thio MD … Dr Esther Bouman-Thio MD …
Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody™ construct CNTO 528 in healthy subjects
JJ Pérez-Ruixo, W Krzyzanski, E Bouman-Thio… - Clinical …, 2009 - Springer
… central and peripheral compartments, respectively, k e was the linear elimination rate constant,
… The parameters k 12 , k 21 and k e were reparameterized in terms of clearance (CL) and …
… The parameters k 12 , k 21 and k e were reparameterized in terms of clearance (CL) and …
Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects
…, S Lyn, Z Xu, M Achira, E Bouman‐Thio… - The Journal of …, 2010 - Wiley Online Library
… Dr Esther Bouman-Thio MD … Dr Esther Bouman-Thio MD … We also thank Rebecca E.
Clemente, PhD, and Robert Achenbach of Centocor Ortho Biotech for editorial support. …
Clemente, PhD, and Robert Achenbach of Centocor Ortho Biotech for editorial support. …
Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial
Y Zhuang, S Lyn, Y Lv, Z Xu, E Bouman-Thio… - Clinical drug …, 2013 - Springer
Background and Objectives Golimumab is an anti-tumor necrosis factor-α human immunoglobulin
G1 κ monoclonal antibody that is efficacious for the treatment of moderate to severe …
G1 κ monoclonal antibody that is efficacious for the treatment of moderate to severe …
Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two phase 1 studies
Y Zhu, Q Wang, B Frederick, E Bouman-Thio… - Clinical drug …, 2013 - Springer
Background and Objective Ustekinumab, a human immunoglobulin G1 kappa (IgG1κ)
monoclonal antibody against interleukin-12/23p40, has been reported to be significantly …
monoclonal antibody against interleukin-12/23p40, has been reported to be significantly …